The in vitro activities of three new 8-methoxychlortetracyclines, Sch 36969, 33256 and 34164 were compared to tetracycline, minocycline and doxycycline. Against aerobic Gramnegative rods Sch 36969 had a geometric mean MIC (GMM)of 4.2^g/ml, about 8-fold more potent than Sch 33256, and similar to all the other compounds. Sch 36969 also had good activity against methicillin-resistant (GMM, 0.21^g/ml) and -susceptible Staphylococci (GMM, 0.14 A*g/ml), Streptococci (GMM, 0.06^g/ml), and most anaerobic bacteria (GMM, <0.5 jug/ml). In general, Sch 36969 was similar to, or more potent than, all the other compounds tested.
34164 were compared to tetracycline, minocycline and doxycycline. Against aerobic Gramnegative rods Sch 36969 had a geometric mean MIC (GMM)of 4.2^g/ml, about 8-fold more potent than Sch 33256, and similar to all the other compounds. Sch 36969 also had good activity against methicillin-resistant (GMM, 0.21^g/ml) and -susceptible Staphylococci (GMM, 0.14 A*g/ml), Streptococci (GMM, 0.06^g/ml), and most anaerobic bacteria (GMM, <0.5 jug/ml). In general, Sch 36969 was similar to, or more potent than, all the other compounds tested.
Serum levels of Sch 36969 in squirrel monkeys were 4-fold lower (AUC, 4.5 /ug>hours/ml) than those of chlortetracycline (AUC, 16.1^g-hours/ml). In mouse protection tests (PD50s) against various strains of bacteria, Sch 36969 was similar in activity to tetracycline, but up to 6-fold less active than chlortetracycline.
The structure activity relationships for these new chlortetracyclines are described.
Three novel derivatives of chlortetracycline (CTC) were isolated from three new strains of Actinomycetales : Sch 33256 from Actinomadura brunnea ATCC392161}, Sch 36969 from a mutant strain of A. brunneaP, and Sch 34164 from Micromonospora vesca ATCC394993). In this paper the in vitro antibacterial activity of these three compounds is compared to tetracycline (TC), doxycycline (DOX), and minocycline (MIN), and the in vivo activity of Sch 36969 is compared to CTC and TC4).
Materials and Methods
Antibiotics Sch 36969, 33256 and 34164 are 8-methoxy derivatives of CTC. The structural differences between them and CTCare shown in Table 1 . These three novel tetracyclines differ from each other in the nature of the substituents at the T and 4a
positions.
Other antibiotics used in this study included tetracycline, doxycycline, minocycline (Sigma Chemical Co., St. Louis, MO) and CTC (U.S.P.C, Inc., Rockville, MD).
MICDeterminations
MICs were determined against 16 Gramnegative aerobic bacteria, 9 1 methicillin-resistant and methicillin-susceptible Staphylococci, and 37 Streptococci by the microtiter method5). MICs for Neisseria gonorrhoeae (1 3 strains), Haemophilus influenzae (19 strains), and anaerobic bacteria were determined by agar dilution5). Serum levels were determined in 6 squirrel monkeys (ca. 1 kg) in a crossover fashion. Monkeys were fasted for 18 hours prior to receiving a single oral dose (20 mg/kg) of antibiotic using a nasogastric feeding tube. Blood samples were taken from the jugular vein at various times and serum samples were assayed for antibiotic activity using a microbiological assay with Bacillus subtilis ATCC6633 as the test organism. Areas under the curves (AUCs)were obtained from serum levels vs. time data by the trapezoidal rule6).
Toxicity (LD50s) Various doses of the antibiotics were administered intravenously (tail vein) to white male CF1 mice (Harlan Sprague Dawley, Inc., Indianapolis, IN) weighing approximately 20 g. The 50 % lethal dose (LD50) for each antibiotic was determined by survival after 96 hours.
Protection Studies (PD50s) The in vivo antibacterial activities of the compoundswere determined in male CF1 mice (ca. 20 g). Groups of 10 mice were infected intraperitoneally with either Escherichia coli, Klebsiella pneumoniae, or Staphylococcus aureus, and were treated with a single oral dose 30 minutes after infection. The 50% protective dose (PD50) values were estimated by probit analysis based on survivors 7 days postinfection70.
Results

In Vitro Antibacterial Activities
The in vitro activities of Sch 36969, 33256, 34164 and related compounds against aerobic, Gramnegative bacilli are shown in Table 2 . The strains were categorized as TC-susceptible (MIC<4^g/ml, 23 strains) or TC-resistant (MIC>8^g/ml, 53 strains).
Against the TC-susceptible strains, Sch 36969 had a geometric mean MIC (GMM) of 4.2jig/ml, similar to those obtained with Sch 34164, TC, DOXand MIN. It was about 8-fold more potent than Sch 33256 (GMM, 33.0 //g/ml). None of the compounds tested had activity against the TC-resistant strains. Therefore, the rest of the in vitro results presented are limited to TC-susceptible strains.
The in vitro MIC results against methicillin-resistant (MethR) and methicillin-susceptible (Meths) Staphylococci are shown in Table 3 . Sch 36969 was the most active compound against MethR and MHB:Mueller-Hinton broth. Meths strains with GMMvalues of 0.21 and 0.14 A*g/ml, respectively. Sch 33256, TC and DOXall had similar GMM values ranging from 0.36 to 0.86^g/ml, while MINhad values greater than 1.0 g/ml. Sch 34164 was least active against Staphylococci with GMMvalues of 2.8 and 5.4^g/ml. The in vitro GMM values of the compounds against Streptococci are shown in Table 4 . Sch 36969, 33256 and 34164 had good activities against each of the streptococcal groups. However, Sch 34164 was less active against Streptococcus faecalis (GMM,5.7 //g/ml). Sch 36969 had excellent activity with a GMMof 0.06 jKg/ml. The GMMvalues of Sch 33256, 34164, TC and DOXranged between 0.15 and 0.45^g/ml, while that of MIN was 1.9 /^g/ml. The in vitro GMM values against Gram-negative and Gram-positive anaerobic bacteria, including strains of Bacteroides, Clostridium, Fusobacterium, Peptococcus and Veillonella are shown in Table 5 . All of the compounds were active against all these strains (GMM, <1.3^g/ml) with the exception of Fusobacterium (GMM, 1.3 to 40.3^g/ml). Sch 36969, 33256, 34164 and TC had similar activities against Neisseria gonorrhoeae (GMM, 0.29 to 1.3 //g/ml, Table 6 ). Against Haemophilus influenzae, Sch 36969, 34164 and TC had equivalent activity (GMM, 1.2 to 2.5^g/ml), while Sch 33256 was 4~8 times less potent (GMM, 8.6 /^g/ml).
Toxicity in Mice
The intravenous LD50 values of Sch 36969, 33256 and 34164 in mice were 85, 90 and 110 mg/kg, respectively, similar to that of CTC (110 mg/kg).
Serum Levels in Squirrel Monkeys Based on its superior in vitro activity, Sch 36969 was chosen for further in vivo studies. Serum levels of Sch 36969 and CTCwere determined in squirrel monkeys. The results are shown in Fig. 1 . Two hours after oral dosing, CTC reached a peak of 3 /^g/ml, while the peak observed for Sch 36969 was 4-fold lower (0.8^g/ml). Peak levels for both compounds were maintained for at least 6 hours. Overall, serum levels reflected the peak differences with those of CTCbeing 4-fold higher (AUC, 16.1 fig -hours/ml) than those of Sch 36969 (AUC, 4.5 /ig -hours/ml).
MouseProtection Tests
The in vivo antibacterial activity of Sch 36969 was compared to those of CTCand TC against two Gram-negative and three Gram-positive strains, and the results are shown in Table 7 . Against the 3 strains of S. aureus tested, PD50 values for Sch 36969 and TC ranged from 0.8 to 12.5 mg/kg. PD50 values for CTCwere lower, ranging from 0.2 to 7.5 mg/kg. Against one strain each of E. coli and K. pneumoniae, Sch 36969 and TC were similar in activity (PD50s 15.0 and 225.0 mg/kg, respectively). CTC was again 4-fold more active (PD5Os, 3.0 and 75.0 mg/kg, respectively). OCT. 1987 Discussion Significant differences were seen in the in vitro activities of Sen 36969, 33256 and 34164. Sch 36969 was the most active derivative against most of the bacterial groups tested. It was especially potent against MethR (GMM, 0.21^g/ml) and Meths (GMM, 0.14 jwg/ml) Staphylococci, Streptococci (GMM,0.06^g/ml), and anaerobic bacteria (GMM,<0.5^g/ml). Sch 36969 was also consistently equal to, or more potent than, TC. The in vitro differences between the three 8-methoxychlortetracyclines can be correlated with the differences in their chemical structures. For example, results indicate that the presence of the methyl group in the 2'-N position reduced the potency of Sch 33256 against aerobic Gram-negative rods (GMM,33.0^g/ml). Similar results have been reported for other 2'-N derivatives^. Although the poor potency of Sch 33256 was also observed against H. influenzae (GMM,8.6 /^g/ml), this was not the case against anaerobic Gram-negative bacilli. Sch 33256 had good activity against Bacteroides fragilis (GMM,0.37^g/ml), similar to the other two derivatives.
The reduced potency of Sch 34164 against MethR (GMM, 5.4 jug/ml) and Meths (GMM, 2.8 A*g/ml) Staphylococci must be due to the presence of the hydroxyl group in the 4a position since this is the only difference between it and Sch 36969.
Structural variations may also account for the observed in vivo differences between Sch 36969 and CTC. The presence of the 8-methoxy group on Sch 36969 may have interfered with its absorption in squirrel monkeys, resulting in 4-fold lower serum levels. Although serum levels were not determined in mice, the data obtained in monkeyssuggest that the reduced efficacy observed in mice mayalso be due to lower serum levels.
